University of California, Los Angeles (UCLA) Researchers Discover Genes Linked To Lymphoma, Opening Way For New Targeted Drugs
The team led by Michael Teitell, M.D., Ph.D., and funded by The Leukemia & Lymphoma Society, used genetically engineered mice to accurately mimic human B-cell cancers. They had previously published research in which they identified frequent genetic abnormalities in cancer cells from NHL patients -- namely defects in the TCL1 gene -- and showed that TCL1 abnormalities can cause NHL in mice when accompanied by additional genetic defects. Now, they have found some of these cancer collaborators.
Teitell's team used a powerful genetic technique called "restriction landmark genomic scanning" (RLGS) to find genes that work with abnormal TCL1 to promote lymphoma formation. These genes are inactivated in lymphomas by defects known as DNA hypermethylation. The breakthrough research, published in the January 29, 2007, issue of the journal Oncogene, is likely to help in the development of new targeted drugs for NHL patients.
The researchers are working to determine which hypermethylation gene defects also occur in human lymphomas, at which point they will be ready to help develop new targeted therapies for NHL patients. Drugs that target DNA hypermethylation are already known to have anti-cancer activity. The drug Decitabine (Dacogen®; SuperGen/MGI Pharma) has recently been approved by the U.S. Food and Drug Administration to treat patients with myelodysplastic syndrome, and is being tested in other cancers. Teitell's findings suggest that such drugs should be tested for anti-lymphoma activity.
Dr. Teitell is the recipient of a Society Scholar Award -- a program that provides funding to highly qualified investigators conducting original research on leukemia, lymphoma or myeloma.
"The goal of the Scholar program is to help advance promising original research with the potential to have the highest impact on blood cancers," said Deborah Banker, Ph.D., the Society's vice president for research communications. "Dr. Teitell's research shows great promise in leading to more effective treatments for NHL patients."
Dr. Teitell said that the Society's support was fundamental in moving his research forward. "I am truly grateful to The Leukemia & Lymphoma Society for having confidence in our work and providing our group with this funding," he said. "I am optimistic that our efforts will improve outcomes for NHL patients."
About The Leukemia & Lymphoma Society
The Leukemia & Lymphoma Society®, headquartered in White Plains, NY, with 66 chapters in the United States and Canada, is the world's largest voluntary health organization dedicated to funding blood cancer research and providing education and patient services. The Society's mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. Since its founding in 1949, the Society has invested more than $483 million in research specifically targeting leukemia, lymphoma and myeloma. Last year alone, the Society made 4.2 million contacts with patients, caregivers and healthcare professionals.
For more information about blood cancer, visit http://www.LLS.org or call the Society's Information Resource Center (IRC), a call center staffed by master's level social workers, nurses and health educators who provide information, support and resources to patients and their families and caregivers. IRC information specialists are available at (800) 955-4572, Monday through Friday, 9 a.m. to 6 p.m. ET.
Contact: Andrea Greif
914.821.8958 914.772.3027 (cell)
Source: The Leukemia & Lymphoma Society